Compare SBGI & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | EVO |
|---|---|---|
| Founded | 1986 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1995 | 2021 |
| Metric | SBGI | EVO |
|---|---|---|
| Price | $14.64 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $21.00 | $7.00 |
| AVG Volume (30 Days) | ★ 395.5K | 255.2K |
| Earning Date | 02-25-2026 | 11-05-2025 |
| Dividend Yield | ★ 6.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,337,000,000.00 | $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.36 | $8.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.89 | $2.84 |
| 52 Week High | $17.88 | $4.80 |
| Indicator | SBGI | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 71.15 |
| Support Level | $14.98 | $3.10 |
| Resistance Level | $15.50 | $3.23 |
| Average True Range (ATR) | 0.46 | 0.08 |
| MACD | -0.11 | 0.07 |
| Stochastic Oscillator | 6.58 | 98.73 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.